• News
  • BioTech

Acadia surges on Parkinson's psychosis drug study

Shares of Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) more than doubled to their highest price in more than three years Tuesday after the company said its drug pimavanserin reduced psychosis in patients with Parkinson's disease.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!